Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 1.00 |
| ▸ | DDB1 | Q16531 | 16/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30828440 | 0.98 | CRBN (0.97) | CRBNDDB1CYP19A1POLBIKZF3 | |
| SCHEMBL31443930 | 0.83 | CRBN (0.70) | CRBNDDB1CYP19A1POLBIKZF3 | |
| SCHEMBL30778437 | 0.82 | CRBN (0.69) | CRBNDDB1CYP19A1POLB | |
| SCHEMBL8182409 | 0.82 | CRBN (0.70) | CRBNDDB1CYP19A1POLBIKZF3 | |
| SCHEMBL7828080 | 0.82 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL25026923 | 0.82 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL8190472 | 0.82 | CRBN (0.70) | CRBNDDB1CYP19A1POLB | |
| SCHEMBL25026926 | 0.82 | CRBN (0.70) | CRBNDDB1POLB | |
| SCHEMBL7827796 | 0.82 | CRBN (0.70) | CRBNDDB1CYP19A1POLB | |
| SCHEMBL8183366 | 0.82 | CRBN (0.70) | CRBNDDB1CYP19A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORP (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4709730-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Celgene Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4661875-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | Celgene Corporation (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4561999-A1 | TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY | Abbvie Operations Singapore Pte. Ltd. (SG) | 2025-06-04 | — | — | EP | disclosed |
| EP-4558495-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250122185-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED N-(2-CHLORO-6-METHYLPHENYL)-2-((6-(6-MEMBERED HETEROCYCLOALKYL)-2-METHYLPYRIMIDIN-4-YL)AMINO)THIAZOLE-5-CARBOXAMIDE ANALOGUES | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2025-04-17 | — | — | US | disclosed |
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024233742-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | CELGENE CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORPORATION | 2024-11-07 | — | — | US | disclosed |
| WO-2024167950-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | CELGENE CORPORATION (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-1996028154-A2 | USE OF ANTI-OESTROGENS AS MALE CONTRACEPTIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-09-19 | — | — | WO | disclosed |
| EP-0495825-B1 | USE OF ANTIGESTAGENS IN THE MANUFACTURE OF MEDICAMENTS | SCHERING AG (DE) | 1996-03-13 | — | — | EP | disclosed |
| WO-1995005828-A1 | PROGESTERONE-ANTAGONISTIC AND ANTI-OESTROGEN COMPOUNDS FOR THE THERAPY OF LEIOMYOMATA UTERI | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-03-02 | — | — | WO | disclosed |
| EP-0310542-B1 | Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours | SCHERING AG (DE) | 1994-06-08 | — | — | EP | disclosed |
| EP-0310541-B1 | ANTIGESTAGENIC AND ANTIOESTROGENIC COMPOUNDS FOR THE INTRODUCTION OF LABOUR AND INTERRUPTION OF PREGNANCY, AS WELL AS FOR THE TREATMENT OF GYNECOLOGIC DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-09 | — | — | EP | disclosed |
| EP-0495825-A1 | USE OF ANTIGESTAGENS IN THE MANUFACTURE OF MEDICAMENTS. | SCHERING AG (DE) | 1992-07-29 | — | — | EP | disclosed |
| WO-1991005557-A1 | USE OF ANTIGESTAGENS IN THE MANUFACTURE OF MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-05-02 | — | — | WO | disclosed |
| US-4888331-A | SIDE EFFECT REDUCTION; | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-12-19 | — | — | US | disclosed |
| EP-0310541-A1 | Antigestagenic and antioestrogenic compounds for the introduction of labour and interruption of pregnancy, as well as for the treatment of gynecologic disorders | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | disclosed |
| EP-0310542-A1 | Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122185-A1 | COMPOSITIONS AND METHODS COMPRISING SUBSTITUTED N-(2-CHLORO-6-METHYLPHENYL)-2-((6-(6-MEMBERED HETEROCYCLOALKYL)-2-METHYLPYRIMIDIN-4-YL)AMINO)THIAZOLE-5-CARBOXAMIDE ANALOGUES | LCK, SRC, MARCKS | CRBN 91/4885DDB1 2069/4885CYP19A1 3852/4885 |
| US-20240368118-A1 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CRBN, AR, SHBG | CRBN 1/4885DDB1 955/4885CYP19A1 85/4885 |
| US-20260109708-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS DEGRADERS OF MK2 KINASE | PSME2, MKRN3, RPS6KA2 | CRBN 172/4885DDB1 2279/4885CYP19A1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.